Project Grant R44NS145848
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $423,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Augusta University Research Institute, Inc. The objective is to develop and evaluate engineered exosomes carrying neuron-targeting peptides and a therapeutic protein (neuroglobin) for treating ischemic stroke. The research will: 1) characterize the engineered exosomes and assess their...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $299,982 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Unandup, LLC, a technology development firm in St. Louis, Missouri. The grant funding supports the development of the Commercialization Readiness Pilot for the FAST (Flow Acceleration for Stroke Thrombolysis) System, an innovative medical device platform designed to safely accelerate the...
- The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $125,685 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Leland Stanford Junior University (Stanford University). The funding will support the development of an injectable hydrogel with an integrated urokinase plasminogen activator (uPA) motif and plasmid DNA (pDNA) platelet-derived growth factor B (PDGFB)-lipoplexes to be loaded into the...
- This $490,049 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research by Shearit LLC to evaluate the efficacy of their Lamiflo drug for reducing ischemic penumbra and core volumes in acute ischemic stroke. The 1-year study will test Lamiflo, a drag-reducing polymer that enhances blood flow, in rat models of middle cerebral artery...
- This $520,025 Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop new peptide nucleic acid (PNA) inhibitors targeting the miR-141-3p microRNA for potential stroke therapy. The research focuses on synthesizing and characterizing more potent gamma-PNA (GPNA) analogs of the miR-141-3p inhibitor, with the primary goal of...
- This Project Grant award of $192,500 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to define the contribution of endothelial cell sphingolipid metabolism to outcomes of acute ischemic stroke in mice. The award, effective December 1, 2024, will enable the University of Utah to leverage innovative murine models and novel ceramide biosynthesis...
- This Project Grant award of $438,625.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at the University of California, San Diego (UCSD) to characterize and augment a novel pro-survival mechanism in neurons during ischemic brain injury. The research aims to investigate the role of the protein INF2 in driving "actinification", a...
- This $498,995 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports the development of a highly parallelized interferometric near-infrared spectroscopy (INIRS) platform for the real-time, non-invasive measurement of cerebral blood flow. The research aims to address the limitations of current stroke diagnosis and monitoring techniques...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $499,953.00 to Stem Pharm, Incorporated to develop and validate a human stem cell-derived neural organoid model for studying temporal lobe epilepsy (TLE). The project aims to create a reproducible, 96-well plate format organoid model that incorporates microglia to better...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $1,150,417 to Gentibio, Inc. to develop a novel allogeneic engineered tissue regulatory T cell (EngrTreg) therapy for the treatment of acute ischemic stroke. The key products or services to be delivered include: The award period runs from August 15, 2025 to July 31, 2027, targeting the development of this first-in-class allogeneic EngrTreg therapy as a new treatment option for this serious neurological condition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 8/19/25 |